You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PI3CA/AKT1/PTEN genetic alterations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2022

Cancer, Solid Tumors Trial in United States (Vevorisertib, Fulvestrant, Paclitaxel)

Terminated
Has Results
  • Cancer
  • Solid Tumors
  • Las Vegas, Nevada
  • +5 more
Jun 14, 2022

Triple Negative Breast Cancer Trial in London (Atezolizumab, Ipatasertib, Paclitaxel)

Active, not recruiting
  • Triple Negative Breast Cancer
  • London, United Kingdom
    Barts Health NHS Trust
Aug 10, 2022

Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)

No longer available
  • Proteus Syndrome
  • +2 more
  • ARQ 092
  • (no location specified)
Jul 31, 2021

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)

Active, not recruiting
  • Advanced Solid Malignancy
  • +13 more
  • Los Angeles, California
  • +33 more
Dec 22, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +6 more
  • Boston, Massachusetts
  • +5 more
Jan 7, 2023

Metastatic or Locally Advanced Malignancies Trial in Germany (Vemurafenib, Cobimetinib, Atezolizumab)

Recruiting
  • Metastatic or Locally Advanced Malignancies
  • Berlin, Germany
  • +5 more
Jan 2, 2023

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Partial PTEN Deletion in Breast Cancer

Not yet recruiting
  • PTEN Gene Deletion
    • (no location specified)
    Oct 27, 2021

    Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

    Recruiting
    • Fallopian Tube Endometrioid Adenocarcinoma
    • +17 more
    • Biopsy
    • +3 more
    • Augusta, Georgia
    • +4 more
    Jan 25, 2023

    Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (MEN1611, Eribulin)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • (no location specified)
    Apr 12, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Los Angeles, California
    • +4 more
    Jul 19, 2022

    PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome Trial in Stanford, Boston, Cleveland (Sirolimus,

    Not yet recruiting
    • PTEN Gene Mutation
    • +2 more
    • Stanford, California
    • +2 more
    Oct 5, 2023

    Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma Trial in Puerto Rico, United States (Ivosidenib)

    Recruiting
    • Recurrent Ependymoma
    • +32 more
    • Birmingham, Alabama
    • +173 more
    Jan 27, 2023

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

    Suspended
    • Anatomic Stage III Breast Cancer AJCC v8
    • +12 more
    • Copanlisib Hydrochloride
    • Eribulin Mesylate
    • Gainesville, Florida
    • +10 more
    Nov 16, 2022

    FGFR Testing by Either ctDNA Blood Testing or Standard Tumor

    Recruiting
    • Metastatic Bladder Cancer
    • Metastatic Urothelial Carcinoma
    • FGFR Testing
    • Calgary, Alberta, Canada
    • +6 more
    Nov 8, 2023

    Study of Proteus Syndrome and Related Congenital Disorders

    Recruiting
    • Proteus Syndrome
    • PIK3CA Related Overgrowth Spectrum
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 27, 2023

      Malignant Solid Tumors Trial in France (Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID))

      Recruiting
      • Malignant Solid Neoplasms
      • Nilotinib (400 mg BID)
      • +6 more
      • Bordeaux, France
      • +6 more
      Dec 15, 2022

      Epiction of Genomic and Genetic Landscape Identifies CCL5

      Completed
      • Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
        • (no location specified)
        Jan 27, 2023

        Cancer Trial in Boston (Abemaciclib)

        Recruiting
        • Cancer
        • Boston, Massachusetts
          Dana Farber Cancer Institute
        Jan 9, 2023

        Gallbladder Cancer Trial in Varanasi (Next generation sequencing)

        Recruiting
        • Gallbladder Cancer
        • Next generation sequencing
        • Varanasi, UP, India
          Banaras Hindu University
        Jun 2, 2022

        HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

        Active, not recruiting
        • HER2-positive Breast Cancer
        • PIK3CA analysis
        • Rome, RM, Italy
          Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        Feb 20, 2023

        Men at High Genetic Risk for Prostate Cancer

        Recruiting
        • Prostatic Neoplasms
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jan 25, 2023

          Advanced Unresectable or Metastatic Solid Malignancy Trial in United States (Entrectinib, Inavolisib, Alectinib)

          Recruiting
          • Advanced Unresectable or Metastatic Solid Malignancy
          • Birmingham, Alabama
          • +50 more
          Aug 10, 2022

          Breast Cancer, Bladder Cancer, Kidney Cancer Trial in New York (PCR/PCR/LDR Strategy)

          Recruiting
          • Breast Cancer
          • +6 more
          • PCR/PCR/LDR Strategy
          • New York, New York
            Memorial Sloan Kettering Cancer Center
          Apr 1, 2022